TY - JOUR AU - Chan, A; Delaloge, S; Holmes, F A TI - ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet Oncol IS - 03 VL - 17 PY - 2016 DO - 10.1016/S1470-2045(15)00551-3 L3 - PubMed-ID: 26874901 SP - 367 EP - 377 ER -